Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$4.68 - $9.26 $30,761 - $60,865
-6,573 Reduced 31.78%
14,107 $70,000
Q2 2023

Aug 14, 2023

SELL
$8.5 - $10.38 $24,225 - $29,583
-2,850 Reduced 12.11%
20,680 $188,000
Q1 2023

May 12, 2023

SELL
$7.53 - $10.95 $971 - $1,412
-129 Reduced 0.55%
23,530 $222,000
Q4 2022

Feb 13, 2023

SELL
$9.44 - $13.09 $10,582 - $14,673
-1,121 Reduced 4.52%
23,659 $236,000
Q3 2022

Nov 14, 2022

BUY
$8.14 - $12.25 $2,954 - $4,446
363 Added 1.49%
24,780 $295,000
Q2 2022

Aug 15, 2022

SELL
$6.99 - $10.0 $4,228 - $6,050
-605 Reduced 2.42%
24,417 $200,000
Q1 2022

May 13, 2022

BUY
$7.26 - $10.7 $54,377 - $80,143
7,490 Added 42.72%
25,022 $199,000
Q4 2021

Feb 14, 2022

BUY
$8.8 - $16.0 $34,311 - $62,384
3,899 Added 28.6%
17,532 $164,000
Q3 2021

Nov 15, 2021

SELL
$15.23 - $21.72 $13,600 - $19,395
-893 Reduced 6.15%
13,633 $215,000
Q2 2021

Aug 13, 2021

BUY
$17.8 - $23.5 $4,485 - $5,922
252 Added 1.77%
14,526 $314,000
Q1 2021

May 14, 2021

SELL
$17.18 - $22.6 $58,549 - $77,020
-3,408 Reduced 19.27%
14,274 $289,000
Q4 2020

Feb 12, 2021

SELL
$11.5 - $17.96 $32,660 - $51,006
-2,840 Reduced 13.84%
17,682 $317,000
Q3 2020

Nov 16, 2020

SELL
$10.62 - $13.12 $56,296 - $69,549
-5,301 Reduced 20.53%
20,522 $239,000
Q2 2020

Aug 14, 2020

BUY
$7.35 - $10.81 $32,928 - $48,428
4,480 Added 20.99%
25,823 $239,000
Q1 2020

May 14, 2020

BUY
$8.38 - $17.34 $91,006 - $188,312
10,860 Added 103.6%
21,343 $222,000
Q4 2019

Feb 13, 2020

BUY
$11.18 - $18.6 $117,199 - $194,983
10,483 New
10,483 $189,000
Q3 2018

Nov 13, 2018

SELL
$34.05 - $55.9 $284,453 - $466,988
-8,354 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$36.15 - $52.5 $301,997 - $438,585
8,354 New
8,354 $421,000

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $770M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.